CellaVision (CEVI.ST) Stock Analysis & AI Equity Report
CellaVision (CEVI.ST) overview
CellaVision (CEVI.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, CellaVision reported revenue of SEK 723m and operating profit of SEK 178m; the year-end share price was 217.50 SEK and market capitalisation was SEK 5,188m. CellaVision is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CellaVision's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-18. Data will be refreshed during report generation.
About CellaVision
CellaVision develops and sells digital hematology microscopy solutions for clinical laboratories. Its portfolio includes analyzers, instruments, reagents, staining systems, software and applications used to automate, standardize and simplify blood and body fluid analysis. The company serves laboratories through global partners and local market support, with products designed to improve workflow efficiency and diagnostic certainty.
Generate the CellaVision report
CellaVision is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CellaVision and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.